羚銳製藥股票討論區

Henan Lingrui Pharmaceutical's high ROE has driven impressive earnings growth. Despite reinvesting a small portion of profits, the company has managed to expand its earnings. Industry analysts predict the company will maintain its current growth rate.

Henan Lingrui Pharmaceutical's low P/E ratio is due to its projected growth being less than the broader market. Investors anticipate limited future growth and are only prepared to pay a lower price for the stock, making a significant share price increase unlikely soon.

EPS growth rate is interpreted as being close to the annualized share price gain of 17% per year. The positive sentiment towards the company is reflected in the share price momentum, which might present an investment opportunity.